Injectable CAB-PrEP
Injectable Cabotegravir (CAB‑PrEP), is expected to be fully available later this month, and represents a major step forward in HIV prevention for people who cannot use oral PrEP.
While it supports progress towards the HIV Action Plan, CAB‑PrEP arrives at a time of rising demand, increasing costs and significant workforce pressures in sexual health services and its introduction brings new operational, tariff and resource considerations that require coordinated planning across local authorities and providers.
Together with the English HIV & Sexual Health Commissioners’ Group (EHSHCG), we have developed a briefing that brings together public health, commissioning and clinical perspectives to support local systems in preparing for the roll‑out.
The briefing will be presented at a special one-hour webinar on Thursday 26th February, aimed at commissioners and service leads. Speakers will include the new President of BASHH, representatives from NHSE as well as EHSHCG.
All stakeholders, including Directors of Public Health, consultants, commissioners and other public health staff are invited to attend to strengthen collective readiness for CAB‑PrEP roll‑out and future HIV prevention innovations.